head in Medical Technology

CEL-SCI to Present Data from Multikine Clinical Trials at National Institutes of Health (NIH), National Cancer Institute (NCI) Seminar Series

... patients with Squamous Cell Carcinoma of the head and Neck. Early intervention in this disease is ... level, brought about by Multikine treatment of head and neck cancer patients. The CEL-SCI / NIH ... collected from patients with advanced primary head and Neck cancer (Oral Squamous Cell Carcinoma) ...

Researchers at the Karmanos Cancer Institute in Detroit Discover Feasibility of Chemotherapy Alternative

... metastases in patients with locally advanced head and neck squamous cell carcinoma. The findings ... M.D., chief medical officer and member of the head and Neck Cancer Multidisciplinary Team at ... professor of medicine and fellow member of the head and Neck Cancer Multidisciplinary Team, conducted ...

Induction Chemotherapy Followed by ChemoRadiotherapy Increased Time-to-Treatment Failure Compared to ChemoRadiotherapy Alone in Patients With Unresectable Locally Advanced Head & Neck Cancer

... - MADRID, May 30 /PRNewswire/ -- The Spanish head and Neck Cancer Cooperative Group (TTCC) ... for patients with unresectable Locally Advanced head and Neck Cancer (LAHNC). The endpoint of ... study enrolled 439 patients with Locally Advanced head and Neck Cancer with good performance status, who ...

New Phase 3 Study of Tapentadol Immediate Release Tablets Published in Current Medical Research and Opinion Journal

... cerebrospinal fluid pressure such as those with head injury and increased intracranial pressure. ... may obscure the clinical course of patients with head injury due to effects on pupillary response and ... should be used with caution in patients with head injury, intracranial lesions, or other sources of ...

BioVex to Report Phase I/II Clinical Trial Results for the Front Line Treatment of Head and Neck Cancer With OncoVEX GM-CSF at the 2009 American Society of Clinical Oncology Meeting

... study in previously untreated patients with head and neck cancer will be presented at the 2009 ... stage III/IV squamous cell cancer of the head and neck (SCCHN)," at a poster session on Friday, ... EDT. Study Rationale Patients with head and neck cancer often present with bulky disease ...

Cleveland Clinic Surgeons Perform Nation's First Near-Total Face Transplant

... Ph.D., Director of Plastic Surgery Research and head of Microsurgery Training, who received worldwide ... surgery, partnering with the Cleveland Clinic head & Neck Institute. Staff members from ... Ph.D., Director of Plastic Surgery Research; head of Microsurgery Training Frank A. Papay, ...

TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia

... flow has been observed such as the effects of head and neck radiation, diabetes and aging. According ... Sjogren's syndrome; radiation treatment to the head and neck; and HIV-related salivary gland disease. ... Sjogren's syndrome, radiation treatment to the head and neck, HIV-related salivary gland disease, ...

Portable CT Increases Chance of Stroke Survival and Recovery

... Before a patient receives tPA, a head CT must be performed to ensure there is no ... much time elapsed between a physician order for a head CT and performance of the scan. The ... be easily added and used to accurately identify a head bleed in a stroke or trauma patient," Dr. Weinreb ...

CEL-SCI Announces Expansion of Exclusive Licensing Agreement for Cancer Drug Multikine

... agreement initially focuses on the areas of head and neck cancer, nasopharyngeal cancer and ... for approval as a first line indication in head and neck cancer. To that end, the Company's ... administration of its cancer drug Multikine to head and neck cancer patients before they receive any ...

CEL-SCI Enters Agreement With National Institutes of Health Clinical Center To Determine the Molecular Basis of Multikine Anti-Tumor Effect

... in patients with squamous cell carcinoma of the head and neck. Should these pre-clinical experiments ... for approval as a first-line indication in head and neck cancer. The company's upcoming Pivotal ... of its anti-cancer drug Multikine to head and neck cancer patients before they receive ...

CEL-SCI Expects to Take Delivery of New Manufacturing Facility on October 8, 2008

... for first-line therapy of previously untreated head and neck cancer patients, and subsequently ... for approval as a first line indication in head and neck cancer. To that end, the Company's ... administration of its cancer drug Multikine to head and neck cancer patients before they receive any ...

Genmab Initiates Study of Zalutumumab With Radiotherapy in Head and Neck Cancer

... With Radiotherapy for the Treatment of Advanced head and Neck Cancer. COPENHAGEN, June 24 ... with radiotherapy for the treatment of advanced head and neck cancer. The study will include a maximum ... best available standard treatment for advanced head and neck cancer. We hope zalutumumab may some day ...

CAPHOSOL(R) Relieves Oral Mucositis (OM) and Improves Quality-of-Life in Cancer Patients Receiving Chemoradiation

... related symptoms, particularly in patients with head and neck cancer and those receiving ... mucositis (NCI Clinical OM Grade 3-4) reported by head and neck cancer patients using CAPHOSOL in this ... OM. Thirty-one percent of the patients had head and neck cancer (HNC), 31 percent had breast ...

STARscanner, STARband Cranial Helmets Making a Difference in the Lives of Children

... hours daily for three to six months, channeling head growth by applying constant, gentle pressure ... eye-safe laser system that scans a child's head in under two seconds. Providing detailed ... Inc. It can be either fabricated from 3-D head shape data, such as a scan from a STARscanner ...

STAR Cranial Centers of Excellence Offer Cutting-Edge Treatment to Dallas Area Children

... about the bumps on her son Christian's head since he was born. Doctors had to utilize forceps ... custom-made specifically for Christian's unique head shape. Treatment for plagiocephaly is most ... if begun at four to six months of age, as minimal head shape correction is possible beyond 18 months of ...

Treximet(TM) (Sumatriptan and Naproxen Sodium) Tablets Approved by FDA for Acute Treatment of Migraine

... moderate to severe headache pain, throbbing head pain, head pain located on one side of the head, head pain aggravated by routine activity, nausea, ...

ActivBiotics Receives Orphan Drug Designation from the European Medicines Agency for Superoxide Dismutase Mimetic, M40403, in Oral Mucositis Indication

... for the prevention of oral mucositis (OM) in head and neck cancer patients receiving radiotherapy. ... of oral mucositis during radiation therapy of head and neck cancers is the major reason for poor ... therapy. There are approximately 140,000 head and neck cancer patients in the European Union; ...

LAP-BAND(R) System Weight-Loss Surgery Associated With More Than 70 Percent Reduced Risk of Death in People With Severe Obesity

... and Education (CORE) in Melbourne, Australia, head of the Centre for Bariatric Surgery in Melbourne ... banding, using the LAP-BAND(R) System. He is head of the Centre for Bariatric Surgery in Melbourne, ... Texas, and is Emeritus Professor of Surgery and head of the Centre for Obesity Research and Education ...

Cethromycin Achieves All Endpoints in Second Pivotal Phase III Trial for Treatment of Pneumonia

... infections like CAP," said Dr. Donald Low, head of the Division of Microbiology in the Department ... 300 papers in peer-reviewed journals. Dr. Low is head of the Department of Microbiology at the ... and Department of Medicine. He is currently head of the Division of Microbiology in the Department ...

Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on CEL-SCI Corporation

... that targets treatment-naive, newly diagnosed head and neck cancer. Multikine(R) is a mixture ... a Phase III clinical trial for advanced primary head and neck cancer. In Phase III, CEL-SCI intends to ... of the standard of care for all advanced primary head and neck cancer patients. Multikine(R) may also ...

Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine

... locally advanced squamous cell carcinoma of the head and neck (SCCHN) are published in the October 25 ... Marshall Posner, MD, Medical Director of the head and Neck Oncology Program at Dana-Farber Cancer ... Department, University Hospital Antwerp and head of the EORTC section ...

Jennerex Presents Clinical Data From JX-594 Demonstrating Tumor Efficacy Against Advanced Liver Cancers

... Prompt Phase 2 Trial of JX-594 in Liver and head and Neck Cancers ... for many cancer types, starting with liver and head and neck cancers," said the study's principal ... planning to initiate a Phase 2a for squamous cell head and neck cancers in early 2008. The company also ...

Taxotere(R) (docetaxel) Granted FDA Approval to Treat Locally Advanced Head and Neck Cancer Prior to Chemoradiotherapy and Surgery

... locally advanced squamous cell carcinoma of the head and neck (SCCHN) before patients ... Marshall Posner, MD, Medical Director of the head and Neck Oncology Program at Dana-Farber Cancer ... such as nausea, anorexia and constipation. head and Neck Cancer, a Deadly Disease More than ...

DAHANCA Initiates Head and Neck Cancer Study With Genmab's HuMax-EGFr

... of a Phase III study of HuMax-EGFr to treat head and neck cancer in cooperation with DAHANCA. ... study of HuMax- EGFr(TM) (zalutumumab) to treat head and neck cancer in cooperation with the Danish head and Neck Cancer Group (DAHANCA). The study will ...

ERBITUX(R) Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study

... overall survival for patients with certain head and neck cancers, and now, with the FLEX data, ... advanced squamous cell carcinoma of the head and neck. ERBITUX as a single agent is indicated ... or metastatic squamous cell carcinoma of the head and neck for whom prior platinum-based therapy ...

Sports Legacy Institute Announces Findings of Forensic Examinations on Wrestler Chris Benoit's Brain

... dedicated to studying the long-term effects of head injuries in sports. SLI President Christopher ... there is a connection between the repeated head injuries suffered by many athletes involved in ... damage that athletes can suffer from repetitive head injuries in contact sports. When the results were ...

Zila Inc. Product Selected to Identify Pre-Cancer in Study of Leading Cancer Treatment Chemotherapeutic - ERBITUX

... (ERBITUX(R)), a leading cancer therapeutic for head and neck cancer developed by ImClone Systems ... is currently marketed for the treatment of head and neck cancer (including upper aerodigestive) ... Plus in such an important study with the leading head and neck cancer therapeutic demonstrates its ...

Sirion Therapeutics Announces Clinical Data Presentations at the 2009 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

... as a treatment for endogenous anterior uveitis based partially on a head to head comparison to Pred Forte(R). The application was accepted in February 2009 ...

Worldwide Cost Estimate for Alzheimer's and Dementia Is US$315.4 Billion

... pressure, type II diabetes, obesity, high fat diets, high cholesterol, head injury, loneliness, lack of education, lack of exercise, depression, low birth weight for gestational age, and smaller head circumference have been found to be risk factors for Alzheimer's and ...

For Iraq Veterans, Headaches Continue After Traumatic Brain Injury

... Feb. 24 /PRNewswire-USNewswire/ -- Many soldiers who experienced mild head trauma or a blast exposure while serving in Iraq or Afghanistan are ... from Iraq or Afghanistan in 2008. All had experienced a concussion, head injury or blast exposure while deployed. Nearly 98 percent of the ...

ADVENTRX Completes Patient Enrollment in ANX-514 Bioequivalence Study

... agent that is approved to treat breast, non-small cell lung, prostate, head and neck & gastric cancers. In 2007, the aggregate worldwide market ... is approved to treat breast, non-small cell lung, prostate, gastric and head and neck cancers. About ADVENTRX Pharmaceuticals ADVENTRX ...

Pieris Reports Development Progress for Anticalin(R) PRS-050, a Next Generation VEGF Antagonist

... dedicated to management of the PRS-050 program in her new function as head of Project Management Angiogenesis. Kristian Jensen joins Pieris ... Chief Executive Officer, stated: "I am delighted to welcome Kristian to head up research activities at Pieris. With his extensive experience in the ...

ESBATech's Antibody Fragment Enters Phase Ib/IIa in Ophthalmology

... Michael A. Thiel, M.D., Ph.D., principal investigator of this study and head of the Department of Ophthalmology at the Kantonsspital in Lucerne, ... and efficacy in the human eye." Peter Lichtlen, M.D., Ph.D., head of Clinical Development at ESBATech AG, commented, "We are very excited to ...

Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology

... sarcoma, gastric, hepatocellular, endometrial, prostate, renal cell, head and neck cancers and hematological malignancies, as well as glioblastoma. ... cell cancer, hepatocellular carcinoma, melanoma, carcinoid, prostate, head and neck, breast, and small cell lung cancer. Responding patients, ...

ASGE and The Pancreatic Cancer Action Network Partner to Raise Awareness About Pancreatic Cancer

... reports of two common, though somewhat ambiguous findings - enlargement of head of pancreas or dilation of the pancreatic duct. EUS and EUS-FNA have ... developed the technique in 1935. A Whipple procedure treats cancer of the head of the pancreas (the widest part) and generally involves removing most of ...

Arpida Announces Review of Iclaprim NDA by FDA Advisory Committee in November 2008

... in the U.S.A., Canada and the European Union. Dr Paul Hadvary, head of Development of Arpida Ltd., commented: "We are delighted to have an ... CFO and Senior Vice President Tel.: +41-61-417-96-65 Paul Verbraeken head of Corporate Communications Tel.: +41-61-417-96-83 ...

Arpida Completes Enrolment in Phase II "Intravenous-to-Oral" Switch Trial With Oral Iclaprim

... outcome as well as safety and tolerability. Dr Paul Hadvary, head of Development of Arpida Ltd., commented: "The speed of enrolment in this ... CFO and Senior Vice President, Tel.: +41-61-417-96-65; Paul Verbraeken, head of Corporate Communications, Tel.: +41-61-417-96-83 ...

Interface Biologics' Anti-Thrombic Additives Show Equivalent Efficacy to Commercial Heparinized Coatings

... TORONTO, Sept. 16 /PRNewswire/ - In a head to head comparison of Interface Biologics Inc. (IBI) Endexo Anti-thrombic ...

BioVex Announces Regulatory Clearance to Commence a Clinical Study With ImmunoVEX HSV2; A Vaccine Candidate for Genital Herpes

... trial of OncoVEXGM-CSF for melanoma and Phase I/II clinical trials for head & neck cancer and pancreatic cancer. Earlier this year, the Company ... Assessment (SPA) procedure and plans to make a second SPA submission for head & neck cancer later in the year. BioVex intends to begin its Phase III ...

Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology

... sarcoma, gastric, hepatocellular, endometrial, prostate, renal cell, head and neck cancers and hematological malignancies, as well as glioblastoma. ... cell cancer, hepatocellular carcinoma, melanoma, carcinoid, prostate, head and neck, breast, and small cell lung cancer. Responding patients, ...